top of page

Who is Stephen Hahn?

Big Pharma and the FDA are/ were both run by Stephen Hahn, but don't worry - I'm sure this isn't a conflict of interests. Just like Bill Gates funding the universities, health care, governments and big pharma institutions.


Dr. Stephen M. Hahn served as the 24th Commissioner of Food and Drugs from December 17, 2019 to January 20, 2021. Dr. Hahn is a physician, scientist and health care leader with an extensive background in patient care, academic research and executive leadership.

Dr. Hahn is a dedicated clinician, having trained in both medical oncology and radiation oncology. In his previous leadership roles, he has always carefully balanced executive management with clinical time to continue to serve oncology patients, his true passion. He specializes in treating both lung cancer and sarcoma.

Throughout his oncology career, Dr. Hahn maintained a keen interest in research, authoring more than 220 peer-reviewed original research articles. His research focuses on the molecular causes of the tumor microenvironment, particularly the study of chemical signals that go awry (known as aberrant signal transduction pathways), and the evaluation of proton therapy as a means of improving the effectiveness of radiation therapy. His experience in medical product development and clinical trials spans drugs, biologics, medical devices, and diagnostics.

Prior to joining the FDA, Dr. Hahn served as the chief medical executive (CME) at The University of Texas MD Anderson Cancer Center, a facility that cares for more than 140,000 patients a year. He has proven executive leadership that spans research, development, clinical trials, patient care, health system management and education. In his role as CME, he was responsible for day-to-day management of the institution, including business, clinical and faculty matters. Under his purview was one of the largest clinical trial groups in the country. Dr. Hahn joined MD Anderson in 2015 as Division Head, Department Chair and Professor of Radiation Oncology. Before joining MD Anderson, he served as chair of the Radiation Oncology department at the University of Pennsylvania’s Perelman School of Medicine from 2005 to 2014.

Dr. Hahn earned the rank of Commander in the U.S. Public Health Service Commissioned Corps while at the National Institute of Health’s National Cancer Institute, where he also completed a fellowship in medical oncology and a residency in radiation oncology. He also a completed residency in internal medicine at University of California, San Francisco. He graduated from the Lewis Katz School of Medicine at Temple University in Pennsylvania and received his bachelor’s in biology from Rice University in Texas.

Flagship Pioneering

Stephen Hahn, M.D., joins Flagship Pioneering following two decades of distinguished leadership in healthcare strategy, clinical experience, and commercialization know-how.

Dr. Hahn, a well-respected oncologist, served as chief medical executive in 2018 at the world-renowned MD Anderson Cancer Center in Houston prior to his FDA appointment. He was named deputy president and chief operating officer in 2017. In that role, he was responsible for the day-to-day operations of the cancer center, which includes managing more than 21,000 employees and a $5.2 billion operating budget. He was promoted to that position two years after joining MD Anderson as division head, department chair, and professor of Radiation Oncology. Prior to MD Anderson, Dr. Hahn served as head of the radiation oncology department at the University of Pennsylvania’s Perelman School of Medicine.

A 1980 Rice University graduate, Dr. Hahn grew up in the Philadelphia area. He earned his medical degree at Temple University and was an internal medicine resident at the University of California San Francisco before completing a fellowship and residency at the National Cancer Institute in Bethesda, Maryland. He joined the University of Pennsylvania Perelman School of Medicine as an assistant professor in 1996 and rose to chair its radiation oncology department from 2005.

bottom of page